Genetically Reduced Antioxidative Protection and Increased Ischemic Heart Disease Risk: The Copenhagen City Heart Study

Background—Extracellular superoxide dismutase (EC-SOD) is an antioxidative enzyme found in high concentrations in the arterial wall. Two to three percent of all people in Denmark carry an R213G substitution, which increases plasma concentration 10-fold. This may reduce arterial wall EC-SOD concentrations, increase intimal LDL oxidation, and therefore may accelerate atherogenesis. Our primary hypothesis was that EC-SOD-R213G predisposes to ischemic heart disease (IHD). The secondary hypothesis was that EC-SOD-R213G offers predictive ability with respect to IHD beyond that offered by measurements of plasma EC-SOD and autoantibodies against oxidized LDL (oxLDL). Methods and Results—The primary hypothesis was tested in a prospective, population-based study of 9188 participants from The Copenhagen City Heart Study with 956 incident IHD events during 23 years of follow-up and retested cross-sectionally with independent case populations of patients with IHD (n=943) or ischemic cerebrovascular disease (ICVD) (n=617). Case populations were compared with unmatched IHD/ICVD-free control subjects from The Copenhagen City Heart Study (n=7992). The secondary hypothesis was tested by using a nested case-control study comparing patients with IHD (n=956) with age- and gender-matched control subjects (n=956). Age- and gender-adjusted relative risk for IHD in heterozygotes (n=221, 2.4%) versus noncarriers (n=8965, 97.6%) was 1.5 (95% CI, 1.1 to 2.1). Retesting confirmed this: Age- and gender-adjusted odds ratios for IHD was 1.4 (1.0 to 2.0) and for ICVD 1.7 (1.1 to 2.7). Additional adjustment for plasma EC-SOD produced an odds ratio for IHD in heterozygotes versus noncarriers of 9.2 (1.2 to 72), whereas adjustment for autoantibodies against oxLDL produced an odds ratio of 2.5 (1.2 to 5.3). Conclusions—Heterozygosity for EC-SOD-R213G is associated with increased IHD risk. Genotyping offers predictive ability with respect to IHD beyond that offered by plasma EC-SOD and autoantibodies against oxLDL.

[1]  S. Marklund,et al.  Extracellular Superoxide Dismutase Deficiency and Atherosclerosis in Mice , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[2]  J. Salonen,et al.  Gene transfer of extracellular superoxide dismutase to atherosclerotic mice. , 2001, Antioxidants & redox signaling.

[3]  P. Schnohr,et al.  Angiotensinogen Mutations and Risk for Ischemic Heart Disease, Myocardial Infarction, and Ischemic Cerebrovascular Disease: Six CaseControl Studies from the Copenhagen City Heart Study , 2001, Annals of Internal Medicine.

[4]  D. Steinberg,et al.  The oxidative modification hypothesis of atherosclerosis: does it hold for humans? , 2001, Trends in cardiovascular medicine.

[5]  P. Schnohr.  The Copenhagen City Heart Study : Østerbroundersøgelsen : tables with data from the third examination 1991-1994 , 2001 .

[6]  M. Boaz,et al.  Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial , 2000, The Lancet.

[7]  S. Kakumu,et al.  Protective Role of Extracellular Superoxide Dismutase in Hemodialysis Patients , 2000, Nephron.

[8]  D. Wilcken,et al.  Plasma extracellular superoxide dismutase levels in an Australian population with coronary artery disease. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[9]  S. Marklund,et al.  Expression of extracellular SOD and iNOS in macrophages and smooth muscle cells in human and rabbit atherosclerotic lesions: colocalization with epitopes characteristic of oxidized LDL and peroxynitrite-modified proteins. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[10]  Markku Peltonen,et al.  Two variants of extracellular‐superoxide dismutase: relationship to cardiovascular risk factors in an unselected middle‐aged population , 1997, Journal of internal medicine.

[11]  K. Hirano,et al.  Substitution of glycine for arginine-213 in extracellular-superoxide dismutase impairs affinity for heparin and endothelial cell surface. , 1997, The Biochemical journal.

[12]  S. Marklund,et al.  The interstitium of the human arterial wall contains very large amounts of extracellular superoxide dismutase. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[13]  S. Marklund,et al.  10-fold increase in human plasma extracellular superoxide dismutase content caused by a mutation in heparin-binding domain. , 1994, The Journal of biological chemistry.

[14]  S. Marklund,et al.  Turnover of extracellular-superoxide dismutase in tissues. , 1994, Laboratory investigation; a journal of technical methods and pathology.

[15]  M. Jauhiainen,et al.  Crossreaction between antibodies to oxidised low-density lipoprotein and to cardiolipin in systemic lupus erythematosus , 1993, The Lancet.

[16]  S. Marklund,et al.  Plasma clearance of human extracellular-superoxide dismutase C in rabbits. , 1988, The Journal of clinical investigation.

[17]  E. Holme,et al.  Superoxide dismutase in extracellular fluids. , 1982, Clinica chimica acta; international journal of clinical chemistry.